Skip to main content

Table 3 Associations between reproductive health characteristics and serological reactivity for HPV16

From: Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study

Characteristic and categories

HPV16 seroreactivity 425/1624 (%)*

OR (95%CI)**

Unadjusted

Adjusted (HPV16 and age)

Oral Contraceptives:

   

Never

60/264 (18.5)

1.0

1.0

<6 years

235/885 (21.0)

1.17 (0.85-1.60)

1.21 (0.88-1.67)

6+ years

130/475 (21.5)

1.20 (0.86-1.69)

1.07 (0.76-1.51)

Inter-uterine Device (IUD):

   

Never

281/1010 (21.8)

1.0

1.0

Ever

144/614 (19.0)

0.84 (0.67-1.05)

0.88 (0.70-1.10)

Condom Use:

   

Never

177/600 (22.8)

1.0

1.0

Rarely

144/574 (20.1)

0.85 (0.66-1.09)

0.88 (0.66-1.08)

Sometimes/always

98/423 (18.8)

0.78 (0.59-1.02)

0.84 (0.63-1.12)

Menstrual Cycle***:

   

Follicular phase

185/745 (19.9)

1.0

1.0

Luteal phase

136/526 (20.5)

1.04 (0.81-1.33)

1.04 (0.81-1.34)

Parity:

   

0-1

55/277 (16.6)

1.0

1.0

2-4

237/943 (20.1)

1.27 (0.92-1.74)

1.16 (0.83-1.61)

5+

133/389 (25.5)

1.72 (1.21-2.44)

1.38 (0.94-2.01)

Abortion:

   

No abortion

216/804 (21.2)

1.0

1.0

One abortion

96/338 (22.1)

1.05 (0.80-1.38)

0.99 (0.75-1.31)

2+ abortions

77/262 (22.7)

1.09 (0.81-1.47)

0.98 (0.72-1.33)

Vaginal Douching:

   

Never/occasional

379/1457 (20.6)

1.0

1.0

Frequent

26/95 (21.5)

1.06 (0.67-1.66)

1.06 (0.67-1.67)

  1. *Frequencies above and below the threshold for the top 20% quintile and percentage with high seroreactivity; **Odds ratios and respective 95% confidence intervals. First category in each variable is the referent; ***At the time of specimen collection: follicular (before 14 days) and luteal phase (after 14 days). Post-menopausal women and women with irregular cycles were not included in the analysis.